Useful

India’s pharmaceutical manufacturing sector plays a decisive role in global medicine supply. A large share of essential generic medicines consumed worldwide originates from Indian facilities, supplying both domestic needs and regulated export markets. At the centre of this manufacturing ecosystem sits Schedule M, the legal framework that defines how pharmaceutical products must be produced, controlled, […]

This page outlines how Indian regulators determine whether a medicine qualifies for approval as a generic, and where applications commonly fall outside abbreviated regulatory pathways. It is intended for readers with baseline familiarity with pharmaceutical development and regulatory systems. This overview reflects how Indian regulators assess generic medicine applications and is intended to support informed

This overview is intended for veterinary distributors, procurement teams, and animal health organisations evaluating generic fluralaner sourcing from India for international markets. Fluralaner has established itself as a core ectoparasiticide in companion animal health, offering long-lasting control of fleas and ticks through systemic administration. As demand for effective parasite control grows worldwide, India is emerging

Regulatory inspections are one of the primary ways authorities determine whether pharmaceutical manufacturers are genuinely operating in compliance with Good Manufacturing Practice or only meeting requirements on paper. Whether conducted by the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization, or national regulators, GMP inspections are designed to evaluate how

The GMP manufacturing process sits at the heart of how medicines are made reliably and at scale. It defines the discipline behind pharmaceutical production: the checks, controls, and documented practices that ensure every batch is manufactured to the same standard as the last. Rather than attempting to “test quality in” at the end, Good Manufacturing

Walk into almost any hospital pharmacy in the world and a significant share of the medicines on the shelves will have been manufactured thousands of kilometres away. Over time, global healthcare systems have come to rely on a small number of countries capable of producing high-quality medicines at scale. India is one of those countries.

Parasite control is a foundational part of canine health care, yet it has historically been one of the most difficult areas to manage consistently. Fleas, ticks, and mites are persistent, resilient, and often thrive in environments where follow-up treatment is inconsistent or impractical. For years, veterinarians relied on frequent topical applications, repeated injections, or older

For many years, long-lasting systemic parasite protection in dogs was associated with higher upfront cost. Extended-duration products offered meaningful advantages in consistency and lifecycle coverage, but pricing positioned them as premium options compared to monthly skin parasite treatments. This premium was significant. Long-acting isoxazolines were commonly priced 30 to 50 percent higher per dose than

Parasites such as fleas, ticks, and mites pose ongoing risks to canine health because their biology does not conform to a simple, short-term treatment window. Fleas can lay up to 50 eggs per day, with immature stages completing development in as little as 2 to 3 weeks under favourable conditions.  Mites often complete their entire

Fluralaner has become a routine consideration in modern canine parasite control, particularly in cases where consistency, duration, and practicality influence treatment decisions. For veterinary professionals, understanding where fluralaner fits within a broader parasite management strategy is essential. It is not simply a long-acting alternative to older products, but a tool with specific strengths, limitations, and